DOCSLIB.ORG

Medicines Formulary

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Medicines Formulary MEDICINES FORMULARY Medicines formulary between MCHFT and primary care as agreed by the Joint Medicines Management Group Welcome to the MCHFT Medicines Formulary. The formulary includes medicines that have been approved by the Joint Medicines Management Group (JMMG) for prescribing within the trust. The purpose of the formulary is to ensure prescribing is evidence based and cost effective. All prescribing within the trust (i.e. inpatient, outpatient and FP10HNC prescribing) must comply with the formulary. This will be monitored on a regular basis. Some drugs may appear in more than one section. Information on prescribing in primary care is available via the Medicines Management Team website: http://www.centralandeasterncheshiremmt.nhs.uk This is a good point of reference to confirm the continuation of medicines in primary care after initiation at MCHFT. Please note medicines contained in the primary care formulary are not automatically formulary at MCHFT. The formulary is arranged in sections corresponding to those in the British National Formulary (BNF) as below; INTRODUCTION .......................................................................................................................................... 2 UPDATES TO THE FORMULARY (LAST UPDATED AUGUST 2019) ....................................................... 4 1. GASTRO-INTESTINAL SYSTEM ............................................................................................................. 7 2. CARDIOVASCULAR SYSTEM .............................................................................................................. 11 3. RESPIRATORY SYSTEM ...................................................................................................................... 17 4. CENTRAL NERVOUS SYSTEM ............................................................................................................ 21 5. INFECTIONS ......................................................................................................................................... 28 6. ENDOCRINE SYSTEM .......................................................................................................................... 31 7. OBSTETRICS, GYNAECOLOGY AND URINARY-TRACT DISORDERS .............................................. 37 8. MALIGNANT DISEASE AND IMMUNOSUPPRESSION ........................................................................ 40 9. NUTRITION AND BLOOD...................................................................................................................... 51 10. MUSCULOSKELETAL AND JOINT DISORDERS ............................................................................... 56 11. EYE ...................................................................................................................................................... 59 12. EAR, NOSE AND OROPHARYNX ....................................................................................................... 63 13. SKIN ..................................................................................................................................................... 65 14. IMMUNOLOGICAL PRODUCTS AND VACCINES .............................................................................. 71 15. ANAESTHESIA .................................................................................................................................... 72 (Last updated August 2019) Page 1 of 73 i Introduction Operation of the Formulary Items available for general prescribing and restricted items are identified according to the following colour coding; MCHFT Formulary Item Colour Code Items available for general prescribing Second line/use on specialist advice Consultant prescribing only Removed from the Formulary/Do not prescribe Where a drug is the subject of a NICE Technology Appraisal (TA) the reference number of the guidance is given below the drug entry. Where a drug has been approved by the Joint Medicines Management Group (JMMG, formerly a committee named JMMC) the month and year of the relevant meeting is also listed below the drug entry. NICE guidance can be found at; Technology Appraisals (TA) http://www.nice.org.uk/guidance/published?type=ta Clinical Guidelines (CG) http://www.nice.org.uk/guidance/published?type=cg MHRA Alerts and recalls on drugs and medical devices https://www.gov.uk/drug-device-alerts This information is summarised in the form of PowerPoint slides on the new SharePoint intranet site. Please search or click ‘Introduction to the MCHFT Formulary' Patients taking a non-formulary drug on admission Treatment with a non-formulary drug may be continued in this instance; however it must be borne in mind that there may be a delay in obtaining a non-formulary drug. Additions to the formulary The addition of a new drug or preparation will only be made after approval by the Joint Medicines Management Group. To request an addition to the formulary a New Product Request (NPR) form must be submitted to the JMMG. This form can be found under Frequently Used Forms- Medicines Management on the old trust intranet. Otherwise please search New Product Request on the new SharePoint intranet. New non-formulary drugs required for an individual patient in exceptional circumstances Such an application for a “one-off” use may be made to the chairperson of the JMMG, if the drug is required before the next JMMG meeting. Please contact Senior Clinical Pharmacist – Medicines Optimisation for more information. Local Health Economy (LHE) Formulary Policy (Vale Royal, South Cheshire and Eastern Cheshire areas). The LHE Formulary is intended to cover prescriptions written in primary care or recommendations by hospital doctors in respect of outpatients or patients leaving hospital after an admission. The Area Prescribing Group (APG) agrees on a formulary status of medicines. These are designated by the following colours: (Last updated August 2019) Page 2 of 73 Primary Care Formulary Item Colour Code • Green = Recommended • Green/Yellow = On formulary • Yellow = A second or third line option within a drug group • Pink (Specialist Recommendation) = Medicines that can safely be initiated in primary care on the recommendation of a specialist • Pink (Specialist Initiation) = Medicines that require specialist initiation and/or stabilisation before prescribing is transferred to primary care • Pink (Shared Care) = Medicines that require a more formal shared-care approach including regular secondary care review and monitoring • Purple = Consultant/ Specialist only prescribing • Red = Discouraged • Grey = Discouraged; not considered suitable for prescribing • Blue = No formulary decision made / formulary position not yet considered (not to be prescribed until a formulary status has been agreed) Free of Charge Medicines A free of charge medicines scheme is defined as an arrangement where a UK licensed or unlicensed medicine is provided free of charge by the pharmaceutical company to an individual patient or an identified cohort of patients. Commissioners and providers will only undertake a free of charge scheme if the principles outlined in the RMOC policy are followed. Please refer to the RMOC July 2018 policy available on the Trust Intranet and on the SPS website (click here) BACK TO TOP (Last updated August 2019) Page 3 of 73 ii Updates to the formulary UPDATES TO THE FORMULARY 2019 Date BNF Update Details Section See formulary entry for full details August 4.1.1 Melatonin prolonged release microtablets 1mg and 5mg (Slenyto®) 2019 8.1.5 Atezolizumab 8.2.3 Blinatumomab 10.2 Nusinersen 13.2.1 Aproderm – Colloidal oat cream July 6.1.2.3 Ertugliflozin 2019 6.3.2 Dexamethasone Liquid 6.4.2 Testogel (1% testosterone gel) 8.2.3 Ocrelizumab 8.2.4 Lenalidomide June 4.6 Droperidol 2019 8.1.5 Abemaciclib Cabozantinib 8.2.3 Durvalumab Nivolumab 8.3.4.2 Enzalutamide 10.1.3 Certolizumab pegol 13.5.3 Tildrakizumab Area Prescribing Group May 2019 update: 6.1.1 Prescribing Commissioning Policy - Freestyle Libre Flash Glucose Monitoring System - May 2019 Reclassification of formulary status as GREY (Removed from the Formulary/Do not prescribe): 1.9.4 Creon 40,000 units Product withdrawn June 2019 11.3.3 Aciclovir eye ointment Product withdrawn June 2019 11.8.1 Lubristil Eye Gel Product withdrawn June 2019 May 8.1.5 Bosutinib 2019 Brentuximab vedotin April Section i. Free of Charge (FOC) Medicines Schemes (RMOC July 2018) 2019 Link to the policy and blank FOC Medicines Form added to the intranet 6.1.2.3 Ertugliflozin 8.1.5 Abemaciclib Brigatinib Daratumumab Pertuzumab Pembrolizumab Sunitinib 8.2.4 Tisagenlecleucel Benralizumab Venetoclax 10.1.3 Abatacept Reclassification of formulary status as GREY (Removed from the Formulary/Do not prescribe): 1.6.2 Co-danthramer capsules & co-danthrusate capsules Product withdrawn August 6.1.1.1 2015 6.6.2 Hypurin Bovine Insulin (all presentations) Product withdrawn August 2017 (Last updated August 2019) Page 4 of 73 Strontium ranelate Product withdrawn July 2017 9.5.1.1 Calcium-Sandoz® syrup Product withdrawn April 2015 March 4.9.1 Opicapone 2019 5.1.7 TauroLock® Catheter Lock Solution 6.1.2.3 Semaglutide (Ozempic®) 8.1.5 Bevacizumab Dabrafenib Encorafenib 9.6.4 Prescribing Guidance for the Management of Vitamin D Deficiency – guidance link added February 1.7.4 Darvadstrocel 2019 3.2 Combisal® metered dose inhaler Salmeterol/fluticasone 25/50, 25/125 & 25/250 5.1.7 Cefoxitin Clofazamine 6.4.1.2 Ulipristal acetate (Esmya®) – Formulary reclassification Updated licensed indication and restrictions Aug
Load more

Recommended publications
  • Reference List of Drugs with Potential Anticholinergic Effects 1, 2, 3, 4, 5
    ANTICHOLINERGICS: Reference List of Drugs with Potential Anticholinergic Effects 1, 2, 3, 4, 5 J Bareham BSP © www.RxFiles.ca Aug 2021 WHENEVER POSSIBLE, AVOID DRUGS WITH MODERATE TO HIGH ANTICHOLINERGIC ACTIVITY IN OLDER ADULTS (>65 YEARS OF AGE) Low Anticholinergic Activity; Moderate/High Anticholinergic Activity -B in combo Beers Antibiotics Antiparkinsonian Cardiovascular Agents Immunosuppressants ampicillin *ALL AVAILABLE AS amantadine SYMMETREL atenolol TENORMIN azaTHIOprine IMURAN cefOXitin GENERIC benztropine mesylate COGENTIN captopril CAPOTEN cyclosporine NEORAL clindamycin bromocriptine PARLODEL chlorthalidone GENERIC ONLY hydrocortisone CORTEF gentamicin (Oint & Sol’n NIHB covered) carbidopa/levodopa SINEMET digoxin LANOXIN, TOLOXIN methylprednisolone MEDROL piperacillin entacapone COMTAN dilTIAZem CARDIZEM, TIAZAC prednisone WINPRED dipyridamole PERSANTINE, ethopropazine PARSITAN vancomycin phenelzine NARDIL AGGRENOX disopyramide RYTHMODAN Muscle Relaxants pramipexole MIRAPEX Antidepressants baclofen LIORESAL ( on intrathecal only) procyclidine KEMADRIN furosemide LASIX amitriptyline ELAVIL cyclobenzaprine FLEXERIL selegiline ELDEPRYL hydrALAZINE APRESOLINE clomiPRAMINE ANAFRANIL isosorbide ISORDIL methocarbamol ROBAXIN OTC trihexyphenidyl ARTANE desipramine NORPRAMIN metoprolol LOPRESOR orphenadrine NORFLEX OTC doxepin >6mg SINEQUAN Antipsychotics NIFEdipine ADALAT tiZANidine ZANAFLEX A imipramine TOFRANIL quiNIDine GENERIC ONLY C ARIPiprazole ABILIFY & MAINTENA
    [Show full text]
  • COPD Agents Review – October 2020 Page 2 | Proprietary Information
    COPD Agents Therapeutic Class Review (TCR) October 1, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. October 2020
    [Show full text]
  • FDA Briefing Document Pulmonary-Allergy Drugs Advisory Committee Meeting
    FDA Briefing Document Pulmonary-Allergy Drugs Advisory Committee Meeting August 31, 2020 sNDA 209482: fluticasone furoate/umeclidinium/vilanterol fixed dose combination to reduce all-cause mortality in patients with chronic obstructive pulmonary disease NDA209482/S-0008 PADAC Clinical and Statistical Briefing Document Fluticasone furoate/umeclidinium/vilanterol fixed dose combination for all-cause mortality DISCLAIMER STATEMENT The attached package contains background information prepared by the Food and Drug Administration (FDA) for the panel members of the advisory committee. The FDA background package often contains assessments and/or conclusions and recommendations written by individual FDA reviewers. Such conclusions and recommendations do not necessarily represent the final position of the individual reviewers, nor do they necessarily represent the final position of the Review Division or Office. We have brought the supplemental New Drug Application (sNDA) 209482, for fluticasone furoate/umeclidinium/vilanterol, as an inhaled fixed dose combination, for the reduction in all-cause mortality in patients with COPD, to this Advisory Committee in order to gain the Committee’s insights and opinions, and the background package may not include all issues relevant to the final regulatory recommendation and instead is intended to focus on issues identified by the Agency for discussion by the advisory committee. The FDA will not issue a final determination on the issues at hand until input from the advisory committee process has been considered
    [Show full text]
  • Drug Tariff Part VIIIA December 2019
    12/2019 Part VIIIA BASIC PRICES OF DRUGS Drug Quantity Basic Price Category Part VIIIA - Basic Prices of Drugs Product List Part VIIIA products A Abacavir 600mg / Lamivudine 30 19000 C Lupin Healthcare 300mg tablets (UK) Ltd Abatacept 125mg/1ml solution for 4 120960 C Orencia ClickJect injection pre-filled disposable devices Abatacept 125mg/1ml solution for 4 120960 C Orencia injection pre-filled syringes Acacia spray dried powder 250 g 1632 C J M Loveridge Ltd Acamprosate 333mg gastro- 168 3770 K A resistant tablets Acarbose 100mg tablets 90 2529 A Acarbose 50mg tablets 90 1458 A Acebutolol 100mg capsules 84 1497 C Sectral Acebutolol 200mg capsules 56 1918 C Sectral Acebutolol 400mg tablets 28 1862 C Sectral Aceclofenac 100mg tablets 60 962 A Acenocoumarol 1mg tablets 100 462 C Sinthrome Acetazolamide 250mg modified- 30 1666 C Diamox SR release capsules Acetazolamide 250mg tablets 112 1029 M Acetic acid 2% ear spray S 5ml 410 C EarCalm Acetone liquid 50 ml 112 A Acetylcysteine 200mg oral powder 30 11250 A sachets sugar free Acetylcysteine 2g/10ml solution for 10 2126 C Martindale infusion ampoules Pharmaceuticals Ltd Acetylcysteine 5% eye drops S 10 ml 3346 C Ilube Acetylcysteine 600mg capsules 30 3998 A Acetylcysteine 600mg effervescent 30 550 C tablets sugar free Aciclovir 200mg dispersible tablets 25 147 A Aciclovir 200mg tablets 25 133 M Aciclovir 200mg/5ml oral 125 ml 3578 A suspension sugar free Aciclovir 3% eye ointment S 4.5 g 934 C Zovirax Aciclovir 400mg dispersible tablets 56 1199 A Aciclovir 400mg tablets 56 310 M Aciclovir
    [Show full text]
  • Cdr Clinical Review Report for Incruse Ellipta
    Common Drug Review Clinical Review Report January 2018 Drug umeclidinium bromide (Incruse Ellipta) Indicated for long-term, once daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive Indication pulmonary disease (COPD), including chronic bronchitis and emphysema. List in a similar manner to other long-acting muscarinic antagonists Listing request (LAMAs) as a maintenance bronchodilator treatment for COPD. Dosage form(s) Dry powder for oral inhalation, 62.5 mcg per inhalation Manufacturer GlaxoSmithKline Canada Inc. (GSK) This review report was prepared by the Canadian Agency for Drugs and Technologies in Health (CADTH). In addition to CADTH staff, the review team included a clinical expert in respirology who provided input on the conduct of the review and the interpretation of findings. Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services. While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect.
    [Show full text]
  • (Lamas) a New Frontier for COPD and Asthma Treatment
    White Paper Long-Acting Muscarinic Agents (LAMAs) A New Frontier for COPD and Asthma Treatment LAMAs in Asthma and COPD Table of Contents 1. Introduction ............................................................................................. 3 2. Tiotropium Bromide ................................................................................. 4 3. Tiotropium + Olodaterol .......................................................................... 7 4. Aclidinium Bromide ................................................................................. 8 5. Aclidinium + Formoterol (ACLIFORM) ....................................................... 9 6. Glycopyrronium Bromide ....................................................................... 10 © 7. Glycopyrronium Bromide + Indacaterol (ULTIBRO )............................... 11 8. Glycopyrronium Bromide + Formoterol .................................................. 13 9. Umeclidinium ........................................................................................ 13 10. Umeclidinium + Vilanterol ..................................................................... 14 11. Triple Therapy ........................................................................................ 16 12. Conclusions ............................................................................................ 16 13. About the Author ................................................................................... 17 14. About CROMSOURCE ............................................................................
    [Show full text]
  • Pipelinetr Ends
    June 2011 PIPELINE TRxENDS PIPELINE TR ENDS is produced by the x 1-3 Promising New Agents 5 Industry Trends University of Massachusetts Medical School’s 4 Projected Generic Entry 5 Additional Promising Clinical Pharmacy Services division and 4 Investigational Indications New Agents distributed to our clients twice yearly. 4 FDA Updates In This Issue Promising New Promising New Agents Agents Aflibercept Drug Name: Aclidinium bromide Drug Name: Aflibercept BLA submitted Manufacturer: Almirall, Forest Manufacturer: Regeneron, Bayer for wet age- Phase III Indication: COPD BLA Indication: Wet AMD related macular Formulation: Dry powder inhaler Formulation: Intravitreal injection degeneration Dimethyl fumarate Aclidinium bromide, a long-acting, inhaled Aflibercept is under FDA review for the treatment NDA submission anticholinergic bronchodilator, is an antagonist at of the neovascular form of age-related macular planned for the M2 and M3 muscarinic receptors. It is being degeneration (wet AMD). By inhibiting vascular relapsing-remitting multiple sclerosis studied for the treatment of chronic obstructive endothelial and placental growth factors, aflibercept pulmonary disease (COPD). may reduce the abnormal growth of blood vessels Projected Three Phase III, randomized, double-blind trials that damage the retina through blood and fluid leaks. Generic Entry compared aclidinium bromide 200 μg and 400 μg In two double-blind, non-inferiority, Phase III ® Nasacort AQ twice daily to placebo in patients with moderate to studies, VIEW 1 (N=1,217) and VIEW 2 (N=1,240), Levaquin® severe COPD. In each study, the primary endpoint patients with wet AMD were randomized to Uroxatral® Anzemet® was the change in morning trough forced expiratory intravitreal aflibercept 0.5 mg monthly, 2 mg monthly, Zyprexa® volume in one second (FEV1), from baseline to week or 2 mg every two months following three monthly Zyprexa® Zydis® 12.
    [Show full text]
  • Profile of Aclidinium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease
    International Journal of COPD Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease Michael W Sims Abstract: Bronchodilators provide the mainstay of pharmacologic therapy for chronic Reynold A Panettieri, Jr. obstructive pulmonary disease (COPD), and anticholinergic bronchodilators, in particular, appear to be the most effective. There are currently two anticholinergic agents available in the US for Pulmonary, Allergy, and Critical Care Division, Airways Biology Initiative, the treatment of COPD (ipratropium bromide and tiotropium bromide), but several others are Department of Medicine, University in various stages of development. Aclidinium bromide, a novel, long-acting, anticholinergic of Pennsylvania School of Medicine, Philadelphia, PA, USA bronchodilator, is currently in Phase III trials for the management of COPD. Available evidence suggests that aclidinium is a safe and well tolerated drug with a relatively rapid onset and a sufficient duration of action to provide once-daily dosing. This article will provide a pharma- cologic profile of aclidinium bromide and review the preclinical and clinical studies evaluating its safety and efficacy in the treatment of COPD. Keywords: aclidinium bromide, bronchodilators, pulmonary disease, chronic obstructive, muscarinic antagonists, pharmacokinetics, pharmacology Introduction Chronic obstructive pulmonary disease (COPD) is characterized, in part, by chronic airflow
    [Show full text]
  • PRAC Draft Agenda of Meeting 11-14 May 2020
    11 May 2020 EMA/PRAC/257460/2020 Human Division Pharmacovigilance Risk Assessment Committee (PRAC) Draft agenda for the meeting on 11-14 May 2020 Chair: Sabine Straus – Vice-Chair: Martin Huber 11 May 2020, 10:30 – 19:30, via teleconference 12 May 2020, 08:30 – 19:30, via teleconference 13 May 2020, 08:30 – 19:30, via teleconference 14 May 2020, 08:30 – 16:00, via teleconference Organisational, regulatory and methodological matters (ORGAM) 28 May 2020, 09:00-12:00, via teleconference Disclaimers Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also change during the course of the review. Additional details on some of these procedures will be published in the PRAC meeting highlights once the procedures are finalised. Of note, this agenda is a working document primarily designed for PRAC members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006, Rev. 1). Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020.
    [Show full text]
  • Eklira Genuair, INN-Aclidinium Bromide
    24 May 2012 EMA/CHMP/169578/2012 Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report Eklira Genuair International non-proprietary name: aclidinium bromide Procedure No. EMEA/H/C/002211 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail [email protected] Website www.ema.europa.eu An agency of the European Union Table of contents 1. Background information on the procedure .............................................. 5 1.1. Submission of the dossier.................................................................................... 5 1.2. Steps taken for the assessment of the product ....................................................... 6 2. Scientific discussion ................................................................................ 7 2.1. Introduction ...................................................................................................... 7 2.2. Quality aspects .................................................................................................. 8 2.2.1. Introduction ................................................................................................... 8 2.2.2. Active Substance............................................................................................. 8 2.2.3. Finished Medicinal Product .............................................................................
    [Show full text]
  • June 2021: Additions and Deletions to the Drug Product List
    Prescription and Over-the-Counter Drug Product List 41ST EDITION Cumulative Supplement Number 06 : June 2021 ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST ABIRATERONE ACETATE TABLET;ORAL ABIRATERONE ACETATE >A> AB QILU 500MG A 212462 002 Jun 25, 2021 Jun NEWA ACETAMINOPHEN; BUTALBITAL TABLET;ORAL BUTALBITAL AND ACETAMINOPHEN >A> AA ALVOGEN 300MG;50MG A 207635 001 Jun 05, 2017 Jun CAHN >A> AA 325MG;50MG A 205120 001 Oct 30, 2015 Jun CAHN >D> AA CNTY LINE PHARMS 300MG;50MG A 207635 001 Jun 05, 2017 Jun CAHN >D> AA 325MG;50MG A 205120 001 Oct 30, 2015 Jun CAHN ACETAMINOPHEN; BUTALBITAL; CAFFEINE TABLET;ORAL BUTALBITAL, ACETAMINOPHEN AND CAFFEINE >A> AA ALVOGEN 325MG;50MG;40MG A 204984 001 Jan 10, 2017 Jun CAHN >D> AA CNTY LINE PHARMS 325MG;50MG;40MG A 204984 001 Jan 10, 2017 Jun CAHN ACETAZOLAMIDE CAPSULE, EXTENDED RELEASE;ORAL ACETAZOLAMIDE >D> AB ! HERITAGE PHARMS INC 500MG A 090779 001 Jul 14, 2011 Jun CAHN >A> AB ! INDICUS PHARMA 500MG A 090779 001 Jul 14, 2011 Jun CAHN ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE POWDER, METERED;INHALATION DUAKLIR PRESSAIR >D> ASTRAZENECA 0.4MG/INH;0.012MG/INH N 210595 001 Mar 29, 2019 Jun CHRS >A> +! 0.4MG/INH;0.012MG/INH N 210595 001 Mar 29, 2019 Jun CHRS ACYCLOVIR OINTMENT;TOPICAL ACYCLOVIR >D> AB ANDA REPOSITORY 5% A 206437 001 Jul 31, 2017 Jun DISC >A> @ 5% A 206437 001 Jul 31, 2017 Jun DISC ACYCLOVIR SODIUM INJECTABLE;INJECTION ACYCLOVIR SODIUM >D> AP EXELA PHARMA EQ 50MG BASE/ML A 207919 001 Jun 17, 2020 Jun CAHN >A> AP NAMIGEN LLC EQ 50MG BASE/ML A 207919 001 Jun 17, 2020 Jun CAHN ALENDRONATE
    [Show full text]
  • Quick Reference Formulary
    Somerset CCG Quick Reference Formulary – First and Second Line Formulary Options Green is the CCG formulary preferred brand Blue is suitable for self care and available to buy OTC May 2021 Chapter 1 Gastro-intestinal system NICE guideline on chronic heart failure 2.8.2 Anticoagulants • Umeclidinium – Incruse Adrenaline NICE Guideline for reflux and 2.2 Diuretic NICE guideline on DVT Ellipta® • Emerade® dyspepsia • Indapamide • Enoxaparin LAMA/LABA Combination Inhalers 3.7 Mucolytics 1.1 Dyspepsia and Reflux disease • Furosemide • Warfarin • Anoro Ellipta® or Duaklir • Carbocisteine Antacids • Spironolactone • DOACs – Dabigatran, Genuair® or Ultibro • Acetylcysteine as NACSYS® • Mucogel® • Eplerenone rivaroxaban, apixaban, Breezhale® or Spiolto Alginate 2.3 Aniti-arrhythmic edoxaban Respimat® Chapter 4 Central Nervous System • Peptac® • Amiodarone 2.9 Antiplatelets Theophylline – prescribe by brand 4.1 Hypnotic and Anxiolytics • Acidex Advance® 2.4 Betablocker • Aspirin as Danamep®, • Theophylline MR – NHS Sleep and Tiredness guide 1.2 Antispasmodic • Bisoprolol clopidogrel, dipyridamole Uniphyllin Continus®, CCG hypnotics and anxiolytics • Mebeverine tabs • Atenolol MR, prasugrel, ticagrelor Nuelin SA® Hypnotics 1.3.5 PPI • Metoprolol 2.12 Lipid Regulating Drugs • Zoplidem, zopiclone, CCG PPI deprescribing algorithm 2.5.5 ACE-inhibitors Statins 3.2 Corticosteroids (prescribe by diazepam • Lansoprazole, omeprazole, NICE guideline on hypertension • Atorvastatin, rosuvastatin, brand) NICE guideline on Anxiolytics pantoprazole, • Lisinopril
    [Show full text]